Evidence map›Paper›PMID 36142723›Full record

ArticleInternational journal of molecular sciences2022

Ana I Álvarez-Mercado, Julio Plaza-Díaz, M Cristina de Almagro, Ángel Gil, José Antonio Moreno-Muñoz, Luis Fontana

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Probiotics as a Barrier AgainstFoods (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. A Combination ofNutrients · 2025
    Article
  5. Frontiers in microbiology · 2024
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ana I Álvarez-MercadoDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-8476-9970
Julio Plaza-DíazDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-5171-9408
M Cristina de AlmagroLaboratorios Ordesa S.L., Parc Científic de Barcelona, 08028 Barcelona, Spain.
Ángel GilDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-7663-0939
José Antonio Moreno-MuñozLaboratorios Ordesa S.L., Parc Científic de Barcelona, 08028 Barcelona, Spain.
Luis FontanaDepartment of Biochemistry and Molecular Biology II, School of Pharmacy, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-8395-8393
Universidad de Granada · ESOrdesa (Spain) · ES

Funding

Laboratorios Ordesa, S. L. and the Center for the Development of Industrial Technology (CDTI) of the Spanish Ministry of Science and Innovation IDI-20170873
6 · The paper itself

Abstract

Previous works have described the activity of

Indexed as

Escherichia coli InfectionsProbioticsAnimalsBifidobacteriumBifidobacterium longum subspecies infantisCaco-2 CellsCytokinesEscherichia coliHumansInfantMiceSwineCytokinesBifidobacterium longum subsp. infantis CECT 7210B. infantis IM-1®Caco-2 cellsco-culturescytokinesdendritic cellsEscherichia coliprobiotics

Identifiers

PMID36142723
PMCPMC9503999
OpenAlexW4296355837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.